

**NIH funding opportunities** 

Faculty of Medicine and Health Sciences: Research Development and Support 13 Jan 2022 (#1)

#### [Click on blue <u>hyperlink</u> for further information]

The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit <u>www.grants.nih.gov</u> or <u>www.sun.ac.za/RDSfunding</u> (current & archive).

Confirm your intent to apply ASAP, but not later than **60 days** before the submission date. Tygerberg Campus: <u>cdevries@sun.ac.za</u> • Stellenbosch Campus <u>lizelk@sun.ac.za</u>

#### **Parent Announcements**

Parent Announcements (PA) for unsolicited are broad funding opportunity announcements allowing applicants to submit investigator-initiated applications. They are open for up to 3 years and use standard due dates.

- PA-20-185 NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)
- PA-20-184 Research Project Grant (Parent R01 Basic Experimental Studies with Humans Required)
- PA-20-183 Research Project Grant (Parent R01 Clinical Trial Required)
- PA-20-200 NIH Small Research Grant Program (Parent R03 Clinical Trial Not Allowed)
- PA-20-195 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Not Allowed)
- PA-20-194 NIH Exploratory/Developmental Research Grant Program (Parent R21 Clinical Trial Required)
- <u>PA-20-196</u> NIH Exploratory/Developmental Research Grant Program (Parent R21 Basic Experimental Studies with Humans Required)

#### **Important Notices**

- NOT-AI-22-017 Notice of Intent to Publish a Funding Opportunity Announcement for Immune Drivers of Autoimmune Disease (U01 Clinical Trial Not Allowed). The National Institute of Allergy and Infectious Diseases (NIAID) intends to publish a Funding Opportunity Announcement (FOA) to solicit applications to establish the Immune Drivers of Autoimmune Disease (IDAD) cooperative research program, which will focus on defining the immunologic states and dynamics that drive autoimmune disease. The main objective of this program is to improve our understanding of the immunologic processes and events that drive not only the course of autoimmune disease but also the preclinical phase and the transition from subclinical autoimmunity to diagnosed autoimmune disease. A secondary objective is to establish innovative approaches that will facilitate further studies by enhancing feasibility of large-scale studies and reducing both financial costs and the burden to subjects. This Notice is being provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. NIAID anticipates funding up to 4 awards, contingent upon the availability of funds and intends to cap direct costs at \$750,000 annually for each award. Estimated Publication Date of Funding Opportunity Announcement: February 14, 2022. First Estimated Application Due Date: July 01, 2022
- <u>NOT-DK-22-007</u> Notice of Intent to Publish a Funding Opportunity Announcement for Advancing Research on Mechanisms and Management of Pain for Diseases and Conditions within NIDDK Mission Areas (R01 Clinical Trial Optional). The purpose of this Notice is to inform the community that the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) intends to publish a Funding Opportunity Announcement (FOA) that will invite broad investigator-initiated research projects proposing novel basic, translational, and clinical studies and efforts to develop new approaches to assess and treat pain for disorders within the National Institute of Diabetes

and Digestive and Kidney Diseases (<u>NIDDK</u>) <u>NIDDK mission areas</u>. This Notice is provided to allow potential applicants sufficient time to develop meaningful collaborations and responsive projects. This will be an open competition. Estimated Publication Date of Funding Opportunity Announcement: February 15, 2022. First Estimated Application Due Date: May 17, 2022.

- NOT-NS-22-047 Notice of Intent to Publish a Funding Opportunity Announcement for BRAIN Initiative Connectivity across Scales (BRAIN CONNECTS): Specialized Projects for Scalable Technologies (U01 Clinical Trial Not Allowed). The NIH Institutes and Centers contributing to the Brain Research through Advancing Innovative Neurotechnologies® (BRAIN) Initiative intend to issue a Funding Opportunity Announcement (FOA) to support Specialized Projects to develop current or emerging technologies to generate comprehensive atlases of brain connectivity, with an emphasis on human, non-human primate (NHP), and mouse. Projects validating approaches using other species are also permitted if well justified. Applications may address any aspects of the data collection, analysis, and dissemination pipelines, to enable faster and more cost-effective generation and interpretation of brain-wide wiring diagrams. Projects will offer distinct capabilities and competencies aimed at developing and optimizing current technologies or entirely new and potentially risky approaches. Estimated Publication Date of Funding Opportunity Announcement: March 15, 2022. First Estimated Application Due Date: July 13, 2022.
- NOT-NS-22-040 Notice of Intent to Publish a Funding Opportunity Announcement for HEAL Initiative: Advancing Health Equity in Pain and Comorbidities (R61/R33 Clinical Trial Required). The National Institute of Neurological Disorders and Stroke (NINDS), with other NIH Institutes and Centers (ICs), intends to promote a new initiative by publishing a Funding Opportunity Announcement (FOA) to solicit applications for research that will advance health equity in pain and comorbidities. The FOA will support research to develop, test, and implement novel, culturally-appropriate pain interventions and/or adapt, test and evaluate efficacy and effectiveness of existing pain interventions, in populations that disproportionately experience negative health outcomes. Desired outcomes of these interventions include reduction of pain and pain-related symptoms, and improvement in overall health outcomes, including function and quality of life. Interventions that target populations that experience health disparities with chronic pain in addition to at least one comorbid condition (OUD, mental health disorders and/or chronic health conditions) are of the highest priority. First Estimated Application Due Date: April 01, 2022.

### **Notices of Special Interest**

- <u>NOT-CA-22-014</u> Notice of Special Interest (NOSI): Research on Interprofessional Teamwork and Coordination During Cancer Diagnosis and Treatment. This Notice of Special Interest (NOSI) highlights the <u>NCI Healthcare</u> <u>Delivery Research</u> Program's interest in receiving applications focused on understanding and improving interprofessional teamwork and coordination during cancer diagnosis and treatment. This notice applies to due dates on or after February 5, 2022, and subsequent receipt dates through October 9, 2024.
- <u>NOT-AA-22-001</u> Notice of Special Interest (NOSI): Epidemiology and Prevention of Alcohol Misuse in Understudied Young Adult Populations; Military, Workforce, and Community College. The purpose of this future grant application solicitation is to balance the National Institute on Alcohol Abuse and Alcoholism (<u>NIAAA</u>) research portfolio by supporting research on alcohol misuse among persons aged 18 to 29 who are not enrolled in four-year colleges or universities. These persons are commonly in the military, workforce, or community college populations, which are understudied relative to their age peers in four-year colleges. Research on epidemiology, prevention, and screening centered on these understudied populations are all encouraged. This notice applies to due dates on or after June 5, 2022 and subsequent receipt dates through September 8, 2025.
- <u>NOT-HG-22-007</u> Notice of Special Interest (NOSI): Methods Development for Genomic Studies of Genetic Variation, Function, and Disease. The National Human Genome Research Institute (NHGRI) is issuing this Notice of Special Interest (NOSI) to encourage applications that develop novel computational or experimental approaches for genomic studies of how genetic variants relate to genomic function, phenotype, and disease. NHGRI seeks applications that will develop methods to provide a better understanding of how genetic variation

relates to function, phenotype, and disease risk or traits. For this NOSI, the term "disease risk or traits" is used broadly, to encompass diseases, risk of diseases, protective effects against diseases, molecular phenotypes, organismal phenotypes, clinical phenotypes or outcomes, traits, responses to therapeutic drugs or vaccines, and other outcomes relevant to human health and disease. This notice applies to receipt dates on February 5, 2022, and subsequent ones through October 5, 2024.

- <u>NOT-OD-22-022</u> Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Basic Mechanisms of Health Effects. The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research examining how electronic nicotine delivery systems (ENDS) affect normal and disease states relevant to human cells, tissues, organs, and behaviors. Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Studies exclusively examining smokeless tobacco or combustible tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. This notice applies to due dates on or after December 2, 2021 and subsequent receipt dates through May 09, 2023.
- <u>NOT-OD-22-023</u> Notice of Special Interest (NOSI): Electronic Nicotine Delivery Systems (ENDS) and Alternative Nicotine and Tobacco Delivery Systems: Population, Clinical and Applied Prevention Mechanisms of Health Effects. The Office of Disease Prevention and participating ICOs are issuing this Notice to communicate our interest in research on electronic nicotine delivery systems (ENDS). Research on alternative nicotine and tobacco delivery systems [e.g., heated tobacco products (also called heat-not-burn)] will also be considered. Research with a focus on other non-combustible nicotine and tobacco products will be considered on a case-by-case basis. Studies should examine population-based, clinical, and applied prevention of disease, including etiology and epidemiology of use, potential risks, benefits and impacts on other tobacco products (e.g., cigarettes, cigars) will be considered non-responsive. This notice applies to due dates on or after December 2, 2021 and subsequent receipt dates through May 09, 2024.
- <u>NOT-OD-22-039</u> Notice of Special Interest (NOSI): Development of Resources and Technologies for Enhancing Rigor, Reproducibility, and Translatability of Animal Models in Biomedical Research. With this Notice of Special Interest (NOSI), Office of Research Infrastructure Programs (ORIP) intends to support exploratory/developmental and highly innovative projects aimed at developing broadly applicable technologies, tools, and resources for validating animal models and enhancing the rigor, reproducibility, and translatability of animal research. This NOSI is for two-year projects that address key animal resource- and technology-related gaps identified in the "Validation of Animal Models and Tools for Biomedical Research" workshop organized by ORIP, NHLBI, NIA, NIDDK, NIGMS, and NINDS. Animal models of interest for this NOSI include, but are not limited to, invertebrate and vertebrate organisms ranging from *C. elegans* and *Drosophila* to zebrafish, mouse, rat, pig, and nonhuman primates. First Available Due Date: February 16, 2022. Expiration Date: May 08, 2024.
- <u>NOT-AI-22-013</u> Notice of Special Interest (NOSI): Advancing Research Needed to Develop a Universal Influenza Vaccine. The purpose of this Notice of Special Interest (NOSI) is to support research that contributes to the areas of interest outlined in <u>"A Universal Influenza Vaccine: The Strategic Plan for the National Institute of Allergy and Infectious Diseases."</u> This notice applies to application receipt dates on or after February 5, 2022 and subsequent receipt dates through January 7, 2025. The proposed research should have clear relevance to the research objectives defined in the strategic plan, which encompasses three major research areas:
  - o Improve understanding of transmission, natural history and pathogenesis of influenza virus infection
  - o Characterize influenza immunity and correlates of immune protection
  - o Support rational design of universal influenza vaccines
- <u>NOT-OD-22-026</u> Notice of Special Interest (NOSI): Administrative Supplement for Research and Capacity Building Efforts Related to Bioethical Issues (Admin Supp Clinical Trial Optional). The NIH Office of Science Policy (OSP) within the Office of the Director (OD) announces the availability of administrative supplements to support 1) research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) certain efforts to develop or augment bioethics research capacity. Applicants may propose to supplement parent awards focused on bioethics or to address a component related to bioethics in a biomedical research study. Note that applications must be within the general scope of the parent

award. This administrative supplement will provide an opportunity for NIH-supported grantees to 1) conduct research on bioethical issues to develop or support the development of an evidence base that may inform future policy directions, and/or 2) develop projects that develop or augment bioethics research capacity. The Office of the Director intends to commit at least \$2,000,000 in FY 2022 to fund approximately 10 awards. Application budget cannot exceed a maximum direct cost of \$100,000. In addition to the direct cost, applicable F&A (indirect) costs can also be requested. Requests may be for one year of support only. First Available Due Date: January 17, 2022. Expiration Date: March 17, 2022.

## **Funding Opportunity Announcements (FOA)**

# 1. Ocular Surface Innervation from Cell Types to Circuit Functions (U01 Clinical Trial Not Allowed) Letter of Intent: 30 days prior to the application due date Hyperlink: <u>RFA-EY-21-004</u> Application Due Date: 7 March 2022. Apply by 5:00 PM local time of applicant organization Type: U01

**Funding Opportunity Announcement**: This Funding Opportunity Announcement (FOA) aims to identify and support collaborative projects that will comprehensively delineate ocular surface innervation – from corneal sensation to pain circuits and tearing reflexes. The Request for Applications (RFA) aims to explore this system at three levels of analysis: morphologic, molecular, and functional. Successful projects will incorporate and integrate at least two of these levels of analysis, and ideally all three. Collaborative multi-disciplinary teams are expected with investigators having complementary areas of expertise. The premise of this FOA is that such basic biology will facilitate a deeper understanding of related pathobiology including neuropathic ocular pain and dry eye disease that will lay a foundation for future translational and clinical research on the anterior segment of the eye.

**Budget**: NEI intends to commit up to \$5 million in FY2022 to fund up to 5 awards. Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years

 2. Research to support the development of alternatives to antimicrobials for use in food-producing animals (U01) Clinical Trial Not Allowed

 Letter of Intent: 30 days prior to the application due date
 Hyperlink: PAR-22-087
 Type: U01

 Application Due Date: April 1, 2022 by 11:59 PM Eastern Time; April 3, 2023 by 11:59 PM Eastern Time. April 1, 2024 by 11:59 PM Eastern Time.
 Type: U01

**Funding Opportunity Announcement**: FDA announces the availability of fiscal year (FY) 2022 funds to support studies that identify the most common drivers for antimicrobial use in animal agriculture and identify potential alternatives to antimicrobials that may reduce the need for antimicrobial use. The funded studies are intended to 1) provide information about animal diseases that are the most significant drivers for antimicrobial use in various animal production settings for the four major food-producing species (i.e., cattle, swine, turkeys, and chickens), and 2) provide information about alternative practices that may help reduce the reliance on such drugs while addressing animal health needs. Such alternatives can include changes in husbandry, biosecurity, vaccination, and other practices. This grant will support the continued advancement of FDA's initiatives related to supporting antimicrobial stewardship in veterinary settings and will support the National Action Plan objectives to engage the animal health community and relevant stakeholders to advance strategies intended to foster antimicrobial stewardship and to improve understanding of antimicrobial use practices in animal agriculture.

**Budget**: FDA /CVM intends to fund up to \$500,000 in fiscal year 2022 in support of this grant program. Funding for FY2023 and FY2024 will be contingent upon annual appropriations and availability of funding. It is anticipated up to 5 awards will be made, not to exceed \$500,000 in total costs (direct plus indirect), per award. Application budgets need to reflect the actual needs of the proposed project and should not exceed \$500,000 in total costs (direct and indirect). The scope of the proposed project should determine the project period. The maximum project period is 5 years.

Research Development and Support Division (RDSD),	Afdeling Navorsingsontwikkeling/Division for Research Development (DRD)
Faculty of Medicine and Health Sciences, Stellenbosch University	Stellenbosch University
5 <sup>th</sup> Floor, Teaching Block, Tygerberg Campus.	2038 Wilcocks Building, Ryneveld Street
Enquiries: <i>Christa</i>	Enquiries: <i>Lizél</i>
e: cdevries@sun.ac.za   t: +27 21 938 9838	e: lizelk@sun.ac.za   t: +27 21 808 2105